SUMMARY
Bupivacaine decreases cardiac contractility in a dosedependent manner. While this probably results primarily from Na + channel block [2] , bupivacaine also appears to block Ca 2+ channels and may decrease release of Ca 1+ from the sarcoplasmic reticulum [3] . Additive cardiovascular depression has been observed in conscious dogs treated with combinations of bupivacaine and the phenylalkylamine calcium antagonist, verapamil [4] . A brief clinical report of a probable adverse interaction between bupivacaine and verapamil has also been published [5] . In contrast, nicardipine, a dihydropyridine calcium channel antagonist, with relatively selective effects on arterial resistance vessels, appears to be protective against bupivacaine toxicity in the rat [6] . Diltiazem, a benzothiazepine calcium antagonist, has effects on the cardiovascular system intermediate between those of verapamil and nicardipine and is used frequently in the treatment of angina and hypertension [7] . It is not known if diltiazem also interacts adversely with bupivacaine.
This study was designed to assess the pharmacodynamic interaction between bupivacaine and diltiazem, by measuring their effects alone and in combination, on regional and global cardiac function in anaesthetized dogs.
MATERIALS AND METHODS
Approval for animal use in this study was granted by the Health Sciences Animal Care Committee of the University of Alberta. Experiments were performed on conditioned mongrel dogs (24-31 kg). Anaesthesia was induced with pentobarbitone 30 mg kg" 1 and mechanical ventilation with an oxygen-enriched air mixture was adjusted to maintain normal endtidal carbon dioxide concentrations. After administration of fentanyl 40 ug kg" 1 and pancuronium 80 |ig kg" 1 , anaesthesia was maintained by a constant infusion (4 ml kg" 1 h" 1 ) of fentanyl 20 ug kg" 1 h" 1 , pentobarbitone 3 mg kg" 1 h" 1 and pancuronium 60 ug kg" 1 h" 1 in 0.9 % sodium chloride. A pulmonary artery thermodilution catheter was introduced via the right external jugular vein and a precalibrated high fidelity pressure transducer tipped catheter was positioned in the left ventricle (LV) via the right femoral artery for measurement of LV pressure and the first derivative of LV pressure (LV dP/dt). A bipolar pacing electrode was placed in the right atrium via a femoral vein. After a left lateral thoracotomy, two piezoelectric crystals (5 MHz, 1.5-2.0 mm diameter) were inserted into the sub-endocardium of the LV so that myocardial segment length (SL) could be measured continuously. After instrumentation, positive end-expiratory pressure (5 cm H 2 O) was applied to the airways to prevent atelectasis. Arterial blood-gas tensions, serum electrolyte concentrations and acid-base state were measured at regular intervals. Sodium bicarbonate and potassium chloride were infused, as required, to prevent development of acidosis or hypokalaemia, respectively.
Heart rate (HR), ECG, arterial pressures, SL, LV pressures (LVP) and LV dP/dt were measured continuously. PR intervals were measured from high speed recordings (100 mm s" 1 ) during 15-s periods of atrial pacing at 2.5 Hz. Cardiac output was determined by thermodilution (Edwards cardiac output computer), each value being the average of four individual measurements. Stroke index (SI), cardiac index (CI) and systemic vascular resistance index (SVRI) were calculated from standard formulae [8] . SL between the pair of LV crystals was measured at end-diastole and at the time of maximal shortening during systole and percent segment shortening during systole (%SS) was calculated. LVP-SL loops were constructed for measurement of pressure-length areas, an index of LV segmental work (LVSW).
Blood samples (5 ml) were collected into heparinized blood collection tubes and plasma was separated and stored at -20 °C until analysis. Plasma concentrations of bupivacaine and diltiazem were analysed by an HPLC method developed in our laboratory. An internal standard, benzyl amphetamine 50 |il of 20 |ig ml" 1 was added to 0.5 ml of each plasma sample. The mixture was vortexed with ethyl acetate 4 ml for 15 min on a vortex shaker and centrifuged at 1000 £ for 10 min. The aqueous layer was frozen on a dry ice-acetone bath, then the organic phase was removed and back-extracted with 0.4 ml of hydrochloric acid 0.01 mol litre" 1 . The organic phase was again removed as above and the aqueous layer was placed under a gentle stream of nitrogen for 5 min. Fifty microlitre of the extract was injected onto a Waters HPLC system (Waters, Mississauga, Ont.) with a u.v. detector set at 214 ran. Separation was achieved by running a mobile phase, consisting of acetonitrile, a mixture of 0.092% orthophosphoric acid and 0.2% triethylamine in water (36:62 % v/v), at 2 ml min" 1 through a Waters Novapak C 18 radial-pak cartridge (4 urn, 8 mm x 10 cm). Calibration curves, constructed by plotting peak area ratio against concentration, were linear in the ranges of 20-1000 ng ml" 1 for diltiazem and 0.5-20 ng ml" 1 for bupivacaine. After instrumentation, a period of 60 min was allowed for stabilization and for optimization of fluid status. Baseline values were recorded at 10-min intervals for 40 min to confirm the stability of the preparation. Animals were then allocated randomly to three groups.
---Group A (bupivacaine group; n = 7), received bupivacaine alone, which was given in small, medium and large doses, each consisting of a bolus dose (200, 400 or 600 ng kg" Group B (diltiazem group; n = 7), received diltiazem alone, which was given in a bolus dose of 400 ug kg" 1 followed by a continuous infusion of 12 ug kg" 1 min" 1 . Haemodynamic variables were recorded every 10 min for 180 min and arterial blood samples obtained for analysis of plasma concentrations at 30 and 40 min, and then every 20 and 30 min thereafter to correspond to the sampling times in group A.
Group C (diltiazem plus bupivacaine; n = 7), received diltiazem as described for group B. After 40 min, and in the presence of continued diltiazem infusion, the procedure for bupivacaine administration, blood sampling and haemodynamic measurements used for group A subjects was repeated.
Statistical analysis
Data are reported as means (SEM). Within-group comparisons were made by analysis of variance for repeated measures followed by the Wilcoxon matched-pairs signed rank test for individual comparisons. These comparisons were applied to baseline values and values obtained during infusion of the three concentrations of bupivacaine in group A; to baseline and each of the diltiazem values in group B; and to diltiazem values and those obtained during only the first two concentrations (because of deathinduced reductions in the sample size) of bupivacaine infusion in group C. Between-group comparisons, estimated by the Mann-Whitney U test, were limited to baseline values and to time points equivalent to the first two concentrations of bupivacaine administered for the same reason. Pharmacokinetic data were subjected to one-way analysis of variance followed by the Wilcoxon matched-pairs signed rank test for individual comparisons. P < 0.05 was considered statistically significant.
RESULTS

Pharmacokinetics
The bupivacaine administration regimen (loading doses followed by continuous infusion) resulted in the rapid attainment of steady state plasma concentrations at each of the three doses (table I) and plasma concentrations at 20 and 30 min varied by less than 10% for each of the three doses. As the infusion rate of bupivacaine increased in group A, the clearance of bupivacaine increased (table I) . When bupivacaine was given in the presence of diltiazem (group C), the plasma concentrations of bupivacaine achieved with the three doses did not differ from those" in the absence of diltiazem (table  II) . However, the co-administration of diltiazem increased the clearance of bupivacaine in the small dose. This increase was maintained during the medium and fast rates of administration of bupivacaine so that clearances for medium and large 223 (16) 243 (12) 248 (15) 275 (21) 292 (25 doses of bupivacaine were similar in the absence and presence of diltiazem. Plasma concentrations of diltiazem were stable for the 180-min period of administration in group B, indicating that the kinetics of diltiazem did not change significantly during the study (table I) . Also, in group C, diltiazem concentrations and clearances were also not altered by the various plasma concentrations of bupivacaine, suggesting that diltiazem elimination was unaltered (table II) .
Pharmacodynamics
Baseline values in all groups were similar and no animals were excluded because of haemodynamic instability (tables III-V). In group A animals, bupivacaine produced negative inotropic, chronotropic and dromotropic effects as demonstrated by dose-dependent decreases in SI, CI, LV dP/dt, %SS and LVSW and increases in LVEDP and paced PR interval (table III) . Mean arterial pressure 265 (4) (MAP) was maintained until plasma concentrations of bupivacaine > 9 mg litre" 1 were attained because of increases in SVRI in response to the reduction in CI.' Thereafter, both SVRI and myocardlal contractility decreased, with consequent circulatory failure at a mean plasma concentration of 12.6 (SEM 1.5) mg litre" 1 (table I) . In group B animals, diltiazem significantly decreased MAP and SVRI from baseline, increased CI but not SI, and prolonged paced PR intervals (table  IV) . HR and the measured indices of cardiac contractility were unchanged. Cardiovascular-alterations then remained constant throughout the 180-min administration period.
In group C, the three doses of bupivacaine had effects on SI, CI, LV dP/dt, %SS and LVSW similar to those in group A animals (table V). An important difference, however, was that in the presence of diltiazem, SVRI did not increase to greater than baseline values, with the result that MAP was not maintained. Although the three doses of bupivacaine decreased the measured indices of cardiac contractility in a similar manner in the absence and presence of diltiazem, comparison of the relationships between CI and SVRI ( fig. 1)' demonstrates that, at equivalent values of SVRI, CI was depressed to a significantly greater extent in the presence of diltiazem. Also, animals in this group were not as responsive to atrial pacing, with all but two animals failing to pace during administration of the greatest dose of bupivacaine. No animals survived beyond this concentration of the drug. The lethal plasma concentration of bupivacaine in the presence of diltiazem (table II) was 7.1 (0.7) mg litre" 1 . This value was significantly (P < 0.01) smaller than in animals treated with bupivacaine alone.
Depression of cardiac conduction and contractility was the predominant cause of death in each group (six of seven in group A and seven of seven in group C). One animal (from group A) died in ventricular fibrillation.
DISCUSSION
In this study we found that the toxicity of bupivacaine was enhanced in the presence of a clinically relevant concentration of diltiazem. Lethal plasma concentrations of bupivacaine were significantly smaller (P < 0.01) in the group of animals in which bupivacaine was infused in the presence of diltiazem (7.1 (0.7) mg litre-1 vs 12.6 (1.5) mg litre" 1 )-Death occurred because of myocardial depression rather than ventricular arrhythmias. The calculated clearance values of diltiazem and bupivacaine were similar given alone and in combination, except for a greater clearance of bupivacaine during infusion of the small dose of bupivacaine in group C.
In group A, bupivacaine per se, at a plasma concentration of 2.79 (0.18) mg litre" 1 decreased LV dP/dt to 75 % of baseline with a further decrease to 60% of baseline values at a mean plasma concentration of 5.97 (0.76) mg litre" 1 . LV %SS, a measure of regional segmental function, was inhibited in a similar manner. These data confirm previous work assessing the effect of bupivacaine on ventricular function [9] . Studies in man are limited, but Scott and co-workers [10] , using echocardiographic indices of function, compared ropivacaine with bupivacaine in volunteers and observed depression of cardiac contractility and conduction with bupivacaine plasma concentrations of 1.0-1.5 mg litre"
1 . Bupivacaine also prolonged paced PR interval in a dose related manner, with failure to respond to atrial pacing observed at plasma concentrations greater than 9.0 mg litre" 1 in group A. Significant prolongation of intra-atrial and A-V nodal conduction times has been observed with bupivacaine plasma concentrations as small as 2 mg litre" 1 [11] . Ventricular arrhythmias are associated with acute bupivacaine toxicity, in both isolated cardiac preparations, intact animals and man [12] [13] [14] . Increased concentrations of circulating plasma catecholamines [15, 16] and decreased plasma concentrations of potassium [17] appear to facilitate bupivacaineinduced arrhythmias. Arrhythmias were not the predominant cause of death in our study. This may have been because of the use of fentanyl as an analgesic, and the rigorous maintenance of plasma potassium and bicarbonate within the normal range.
The therapeutic plasma concentration of diltiazem is between 150 and 250 ug litre" 1 [18] and is similar to that attained in this study. Diltiazem at a mean plasma concentration of 250 ug litre" 1 had a minimal effect on the measured indices of contractility, but it decreased MAP, SVRI and A-V conduction velocity. Griffin and co-workers [19] also studied the cardiovascular effects of diltiazem infusion in fentanyl-supplemented, anaesthetized dogs. They reported decreases in MAP and SVRI and increases in CI from baseline values at a mean plasma concentration of 363 ug litre" 1 . Cardiac contractility, as measured by LV dP/dt, was unaltered. With a greater plasma concentration (1483 ug litre" 1 ), LV dP/dt was still unchanged from baseline, while MAP, SVRI and A-V conduction velocity decreased further and CI increased [19] . The increase in CI appeared to parallel the decrease in afterload induced by diltiazem. Skarvan and Priebe [20] , found no adverse effects on global right or left ventricular function with diltiazem concentrations equivalent to those achieved in this study. From the foregoing, one can conclude that acute administration of diltiazem in the anaesthetized animal does not alter cardiac contractility.
Adverse interactions of diltiazem with other cardiodepressant drugs (e.g., inhalation anaesthetic agents) have been studied extensively [21] [22] [23] [24] . An adverse interaction between lignocaine and diltiazem has also been described [25] ; however, that study was performed in dogs anaesthetized with isoflurane, which may have confounded the results. Our study suggests that the negative inotropic and chronotropic effect of large plasma concentrations of bupivacaine is enhanced in the presence of diltiazem. The diltiazem-induced reduction in SVRI was initially protective and preserved CI. However, an abrupt deterioration in contractility and conduction was observed in group C animals with a significantly smaller plasma concentration of bupivacaine than in group A. In the presence of diltiazem, the margin of safety of bupivacaine was reduced approximately two-fold. While direct comparisons between this adverse interaction and that described for verapamil and bupivacaine [4] cannot be made, it appears that small concentrations of bupivacaine may be less hazardous in combination with diltiazem than with verapamil.
Our findings may be explained by a depression of Ca I+ fluxes by bupivacaine which result in greater negative inotropy when Ca 2+ influx has been previously depressed by diltiazem. Alternatively, the observed effects may reflect a pharmacokinetic interaction. Bupivacaine demonstrates concentration-dependent protein binding [26] , with free bupivacaine concentrations increasing from 5% of total plasma concentration in the 1^1 mg litre" 1 range to 50% at concentrations of 12 mg litre" 1 . In addition, diltiazem is subject to displacement in vitro by bupivacaine [27] . Although the effect of diltiazem on bupivacaine binding in vivo is not known, it is possible that bupivacaine may be displaced by diltiazem. This may explain the sudden deterioration in cardiac function observed in group C and the increase in the clearance of bupivacaine noted during infusion of the small dose of bupivacaine in group C.
